Patent · US Active

Stem cell derived islet differentiation

US11999971B2 · kind B2 · utility

4Cited by

69References

20Claims

0Family size

Assignee

Vertex Pharmaceuticals Incorporated · US

Inventors

Felicia J. Pagliuca · Boston, US
George Harb · Boston, US
Lillian Ye · Billerica, US

Key dates

Filing date	Nov 14, 2022
Grant date	Jun 4, 2024
Priority date	—
Expiry date	Nov 14, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2506/45
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.